Trial · NCT05526989
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
NCT05526989, Phase 2, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma. Trials, record NCT05526989. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05526989
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
- NCT number
- NCT05526989
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 25 participants, estimated
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Conditions
- Penile Carcinoma
- Interventions
- Dostarlimab, Niraparib
- First posted
- 2022-09-02
- Last updated
- 2025-12-04
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) | Up to 24 months | Overall response rate is defined as the number of patients with best overall response of complete response or partial response divided by total number of participants by immune Response Evaluation Criteria in Solid Tumors (iRECIST) 1.1. |
| Secondary | Progression Free Survival (PFS) | Up to 24 months | Progression free survival is defined as the duration of time from the start of treatment to the first documentation of tumor progression or death. |
| Secondary | Overall Survival (OS) | Up to 24 months | Overall survival is defined as the duration of time from the start of treatment to death due to any cause. |
| Secondary | Duration of Response (DOR) | Up to 24 months | Duration of response is defined as the time from the date of disease response to the date of disease progression. Participants who do not experience disease progression will be censored at the date of last follow up or last visit. |
| Secondary | Overall Response Rate (ORR) | Up to 24 months | Overall response rate is defined as the number of participants with a best overall response of complete response or partial response per Response Evaluation Criteria in Solid tumors (RECIST)1.1 divided by the total number or participants. |
| Secondary | Disease Control Rate (DCR) | Up to 24 months | Disease control rate is defined as the percentage of patients who have achieved best overall response of complete response, partial response, or stable disease per Response Evaluation Criteria in Solid Tumors (RECIST)1.1. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41163621 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05526989
GET https://conductscience.org/api/trials/v1/NCT05526989/registered